265 related articles for article (PubMed ID: 33629254)
1. CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients.
Hernandez-Cedeño M; Venegas-Rodriguez R; Peña-Ruiz R; Bequet-Romero M; Santana-Sanchez R; Penton-Arias E; Martinez-Donato G; Guillén-Nieto G; Dominguez-Horta MDC
Cell Stress Chaperones; 2021 May; 26(3):515-525. PubMed ID: 33629254
[TBL] [Abstract][Full Text] [Related]
2. A peptide derived from HSP60 reduces proinflammatory cytokines and soluble mediators: a therapeutic approach to inflammation.
Domínguez-Horta MDC; Serrano-Díaz A; Hernández-Cedeño M; Martínez-Donato G; Guillén-Nieto G
Front Immunol; 2023; 14():1162739. PubMed ID: 37187739
[TBL] [Abstract][Full Text] [Related]
3. CIGB-814, an altered peptide ligand derived from human heat-shock protein 60, decreases anti-cyclic citrullinated peptides antibodies in patients with rheumatoid arthritis.
Corrales O; Hernández L; Prada D; Gómez J; Reyes Y; López AM; González LJ; Del Carmen Domínguez Horta M
Clin Rheumatol; 2019 Mar; 38(3):955-960. PubMed ID: 30415439
[TBL] [Abstract][Full Text] [Related]
4. Anti-Inflammatory Activity of CIGB-258 against Acute Toxicity of Carboxymethyllysine in Paralyzed Zebrafish via Enhancement of High-Density Lipoproteins Stability and Functionality.
Cho KH; Kim JE; Nam HS; Kang DJ; Na HJ
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077532
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and pharmacokinetic profiles of an altered peptide ligand derived from heat-shock proteins 60 in Lewis rats.
Del Carmen Domínguez M; Cabrales A; Lorenzo N; Padrón G; Gonzalez LJ
Cell Stress Chaperones; 2020 Jan; 25(1):133-140. PubMed ID: 31802366
[TBL] [Abstract][Full Text] [Related]
6. Jusvinza, an anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill COVID-19 patients. An observational study.
Venegas-Rodríguez R; Serrano-Díaz A; Peña-Ruiz R; Santana-Sánchez R; Hernández-Cedeño M; Rittoles Navarro A; Grecesqui-Cruz I; Pérez-Aguilera L; Segura-Fernández A; Rosario-Cruz L; Martínez-Donato G; Guillén-Nieto G; Domínguez-Horta MDC
PLoS One; 2023; 18(2):e0281111. PubMed ID: 36730325
[TBL] [Abstract][Full Text] [Related]
7. A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.
Hasan D; Shono A; van Kalken CK; van der Spek PJ; Krenning EP; Kotani T
Purinergic Signal; 2022 Mar; 18(1):13-59. PubMed ID: 34757513
[TBL] [Abstract][Full Text] [Related]
8. Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality.
Moradian N; Gouravani M; Salehi MA; Heidari A; Shafeghat M; Hamblin MR; Rezaei N
Eur Cytokine Netw; 2020 Sep; 31(3):81-93. PubMed ID: 33361013
[TBL] [Abstract][Full Text] [Related]
9. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
[TBL] [Abstract][Full Text] [Related]
10. Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction.
Wang J; Yang X; Li Y; Huang JA; Jiang J; Su N
Virol J; 2021 Jun; 18(1):117. PubMed ID: 34088317
[TBL] [Abstract][Full Text] [Related]
11. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
Ramasamy S; Subbian S
Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688
[TBL] [Abstract][Full Text] [Related]
12. Selection of the Appropriate Control Group Is Essential in Evaluating the Cytokine Storm in COVID-19.
Vassiliou AG; Dimopoulou I; Jahaj E; Keskinidou C; Mastora Z; Orfanos SE; Kotanidou A
In Vivo; 2021; 35(2):1295-1298. PubMed ID: 33622933
[TBL] [Abstract][Full Text] [Related]
13. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.
Iglesias-Julián E; López-Veloso M; de-la-Torre-Ferrera N; Barraza-Vengoechea JC; Delgado-López PD; Colazo-Burlato M; Ubeira-Iglesias M; Montero-Baladía M; Lorenzo-Martín A; Minguito-de-la-Iglesia J; García-Muñoz JP; Sanllorente-Sebastián R; Vicente-González B; Alemán-Alemán A; Buzón-Martín L
J Autoimmun; 2020 Dec; 115():102537. PubMed ID: 32843231
[TBL] [Abstract][Full Text] [Related]
14. Discrimination of COVID-19 From Inflammation-Induced Cytokine Storm Syndromes Using Disease-Related Blood Biomarkers.
Kessel C; Vollenberg R; Masjosthusmann K; Hinze C; Wittkowski H; Debaugnies F; Nagant C; Corazza F; Vély F; Kaplanski G; Girard-Guyonvarc'h C; Gabay C; Schmidt H; Foell D; Tepasse PR
Arthritis Rheumatol; 2021 Oct; 73(10):1791-1799. PubMed ID: 33880885
[TBL] [Abstract][Full Text] [Related]
15. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.
Filgueira LM; Cervantes JB; Lovelle OA; Herrera C; Figueredo C; Caballero JA; Sánchez N; Berrio J; Lorenzo G; Cepeda M; Ramos M; Saavedra D; Añe-Kouri AL; Mazorra Z; Leon K; Crombet T; Caballero A
Immunotherapy; 2021 Mar; 13(4):289-295. PubMed ID: 33397150
[TBL] [Abstract][Full Text] [Related]
16. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
La Rosée F; Bremer HC; Gehrke I; Kehr A; Hochhaus A; Birndt S; Fellhauer M; Henkes M; Kumle B; Russo SG; La Rosée P
Leukemia; 2020 Jul; 34(7):1805-1815. PubMed ID: 32518419
[TBL] [Abstract][Full Text] [Related]
17. Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis.
Udomsinprasert W; Jittikoon J; Sangroongruangsri S; Chaikledkaew U
J Clin Immunol; 2021 Jan; 41(1):11-22. PubMed ID: 33128665
[TBL] [Abstract][Full Text] [Related]
18. APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4+ CD25+ T cells from peripheral blood of rheumatoid arthritis patients.
Barberá A; Lorenzo N; Garrido G; Mazola Y; Falcón V; Torres AM; Hernández MI; Hernández MV; Margry B; de Groot AM; van Roon J; van der Zee R; Broere F; van Eden W; Padrón G; Domínguez Mdel C
Int Immunopharmacol; 2013 Dec; 17(4):1075-83. PubMed ID: 24177275
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Mortality in Critically Ill COVID-19 Patients Demanding High Oxygen Flow: A Thin Line between Inflammation, Cytokine Storm, and Coagulopathy.
Popadic V; Klasnja S; Milic N; Rajovic N; Aleksic A; Milenkovic M; Crnokrak B; Balint B; Todorovic-Balint M; Mrda D; Zdravkovic D; Toskovic B; Brankovic M; Markovic O; Bjekic-Macut J; Djuran P; Memon L; Brajkovic M; Todorovic Z; Hadzi-Djokic J; Jovanovic I; Nikolic D; Zdravkovic M
Oxid Med Cell Longev; 2021; 2021():6648199. PubMed ID: 33968298
[TBL] [Abstract][Full Text] [Related]
20. CIGB-258 Exerts Potent Anti-Inflammatory Activity against Carboxymethyllysine-Induced Acute Inflammation in Hyperlipidemic Zebrafish via the Protection of Apolipoprotein A-I.
Cho KH; Nam HS; Kim JE; Na HJ; Del Carmen Dominguez-Horta M; Martinez-Donato G
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
